source
- Roivant's inhaled drug mosliciguat achieves positive Phase 2 results in interstitial lung diseaseRoivant Sciences reported that its inhaled candidate mosliciguat has successfully completed a Phase 2 trial in patients with interstitial lung disease. The study met its primary endpoint, showing a…
- Pharvaris reports injectable-like efficacy from once-daily oral pill for rare genetic diseasePharvaris announced that its experimental oral formulation of deucrictibant achieved efficacy comparable to injectable versions in a once-daily pill. The drug is an extended-release version intend…